Teva Pharmaceutical Indus (TEVA) Stock Price, Quote, News & History | Benzinga

Teva Pharmaceutical Industries Ltd (TEVA) Stock Price, Quote, News & History

TEVANYSE

Trade with Public

Trade with Public

$31.22

-0.07-0.22%

At close: Apr 22, 5:00 PM EST

$31.30

0.080.26%

After Hours: 6:48 PM EST

Earnings: Q1 2026 Earnings in 7 days from now on Wed Apr 29th, before the market open

Conference Call: Conference call scheduled in 7 days at 8:00 AM

Click to view the webcast

OverviewNews Earnings Options Guidance Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$31.50

Close

$31.22

Volume / Avg.

3.51M / 7.73M

Day Range

$30.89 - $31.68

52 Wk Range

13.04 - 37.35

Market Cap

$36.45B

P/E Ratio

25.86

Dividend Yield

-

Exchange

NYSE

RSI

53

Short Interest

2.33%

Days to Cover

3.83

Recent Teva Pharmaceutical Industries Ltd News

Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda

Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipeline amid bullish analyst targets.

Vandana Singh

FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application

FDA accepts Teva's application for the monthly schizophrenia injection TEV-749 as shares show mixed momentum signals.

Vandana Singh

Corcept Therapeutics Stock Plunges As Court Clears Teva Generic

Corcept Therapeutics shares plunged Thursday morning after a federal appeals court upheld a ruling that Teva Pharmaceuticals' proposed generic does not infringe two Korlym-related patents.

Henry Khederian

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

1.65B

Investing Cash Flow (TTM)

737.00M

Financing Cash Flow (TTM)

-2.15B

Free Cash Flow (TTM)

1.15B

Capital Expenditure (TTM)

-501.00M

Net Change in Cash (TTM)

235.00M

Analyst Trends and Forecast

3

Jan

2

Feb

1

Mar

1

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.5

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$51.15B

PE Ratio (TTM)

25.86

PE Ratio (FWD)

11.52

PEG Ratio (TTM)

1.56

PS Ratio (TTM)

2.11

PB Ratio (TTM)

4.61

Earnings Yield % (TTM)

3.87%

Earnings Yield % (FWD)

8.68%

EV / EBITDA (TTM)

16.28

Price / EBITDA (TTM)

11.59

Price / Free Cash Flow (TTM)

31.70

Book Value / Share

$6.79

Company Debt

Total Debt

$16.81B

LT Debt

$14.99B

LT Debt Issuance (TTM)

$2.30B

LT Debt Repayment (TTM)

-$4.11B

Total Cash

$3.56B

Debt to Equity

2.16

Issuance of Debt (TTM)

-$1.81B

Repayment of Debt (TTM)

-$4.11B

Key Statistics

Open

$31.50

Close

$31.22

Volume / Avg.

3.51M / 7.73M

Day Range

$30.89 - $31.68

52 Wk Range

13.04 - 37.35

Market Cap

$36.45B

P/E Ratio

25.86

Dividend Yield

-

Exchange

NYSE

RSI

53

Short Interest

2.33%

Days to Cover

3.83

About

Sector

Health Care

Industry

Pharmaceuticals

Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Teva Pharmaceutical Indus (TEVA) stock?

A

You can purchase shares of Teva Pharmaceutical Indus (NYSE:TEVA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Teva Pharmaceutical Indus (TEVA) competitors?

A

Other companies in Teva Pharmaceutical Indus’s space includes: Novo Nordisk AS (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and Terns Pharmaceuticals Inc (NASDAQ:TERN).

Q

What is the forecast, or price target, for Teva Pharmaceutical Indus (TEVA) stock?

A

Teva Pharmaceutical Indus has a consensus price target of $31.46.

Q

What is the current price for Teva Pharmaceutical Indus (TEVA)?

A

The stock price for Teva Pharmaceutical Indus (NYSE: TEVA) is $31.3 last updated April 22, 2026 at 6:48 PM EDT.

Q

Does Teva Pharmaceutical Indus (TEVA) pay a dividend?

A

There are no upcoming dividends for Teva Pharmaceutical Indus.

Q

When is Teva Pharmaceutical Indus (NYSE:TEVA) reporting earnings?

A

Teva Pharmaceutical Indus does not have any upcoming earnings scheduled.

Q

Is Teva Pharmaceutical Indus (TEVA) going to split?

A

There is no upcoming split for Teva Pharmaceutical Indus.

Q

What sector and industry does Teva Pharmaceutical Indus (TEVA) operate in?

A

Teva Pharmaceutical Indus is in the Health Care sector and Pharmaceuticals industry. They are listed on the NYSE.

People Also Watch

Novo Nordisk AS

Johnson & Johnson

Terns Pharmaceuticals Inc

Axsome Therapeutics Inc